Bacteriophage Therapy Market Synopsis:
The Bacteriophage Therapy Market Was Valued at USD 1.32 Billion in 2023 and is Projected to Reach USD 1.87 Billion by 2032, Growing at a CAGR of 3.89 % from 2024 to 2032.
The Bacteriophage Therapy Market is growing in popularity as a promising option to traditional antibiotics, fueled by increasing worries about antibiotic resistance and the drawbacks of standard treatments for bacterial infections. Bacteriophages, which are viruses that target and kill bacterial cells with precision, provide a specific method to fight bacterial infections without causing harm to beneficial microbiota. This special method is very attractive for treating infections that are resistant to multiple drugs, especially in patients who cannot handle antibiotics or have tried all other options. Consequently, research institutions, biotechnology companies, and healthcare providers are more and more investigating bacteriophage therapy as a possible answer to the worldwide issue of antibiotic resistance.
Major investments in research and development are driving the market's expansion, supporting the creation of bacteriophage treatments for a range of uses like treating wounds, respiratory illnesses, and gastrointestinal issues. Furthermore, the increasing prevalence of healthcare-associated infections (HAIs) and infectious diseases on a global scale, along with regulatory backing for alternative therapies, is fuelling the need for bacteriophage-based solutions. Although there are obstacles related to regulations and worries about the standardization of bacteriophage preparations, progress in genetic engineering and synthetic biology is leading to improved bacteriophage efficacy and broader clinical usefulness.
North America and Europe are currently at the forefront of the bacteriophage therapy market because of substantial research funding, government efforts, and advanced healthcare infrastructure. Nevertheless, there is a rising interest in the Asia-Pacific region due to the surge in antibiotic resistance and prevalence of infectious diseases, which enhance the importance of bacteriophage therapies. Due to continuous clinical trials and increasing knowledge among healthcare professionals, the bacteriophage therapy market is likely to experience significant expansion, fueled by advancements in bacteriophage customization, delivery methods, and potential uses in precision medicine.
Bacteriophage Therapy Market Trend Analysis:
Rising Adoption in Antibiotic-Resistant Infections Treatment
- One of the most significant trends in the Bacteriophage Therapy Market is its adoption as a treatment option for antibiotic-resistant infections. With the rapid increase in antibiotic resistance, traditional treatment methods are becoming less effective, leading to a growing need for alternative solutions. Bacteriophage therapy offers a targeted approach by utilizing viruses that specifically attack pathogenic bacteria, preserving beneficial bacteria and reducing side effects associated with broad-spectrum antibiotics. This trend is driving investment from pharmaceutical and biotech companies aiming to develop bacteriophage therapies specifically designed to address multidrug-resistant pathogens. As awareness and clinical data supporting its efficacy increase, bacteriophage therapy is increasingly positioned as a complementary or alternative solution to antibiotics in the fight against resistant infections.
Expansion of Bacteriophage Customization and Delivery Technologies
- Another emerging trend is the advancement in customization and delivery technologies for bacteriophage therapy, enabling more precise and effective treatments. Through advancements in genetic engineering, bacteriophages can now be tailored to enhance their potency and specificity, allowing for more targeted approaches to specific bacterial strains. Additionally, innovative delivery methods, including encapsulation and nanoparticle delivery systems, are being developed to protect bacteriophages from immune system attacks and enhance their efficacy. These technologies not only improve the safety profile of bacteriophage therapy but also broaden its potential applications, from wound care and topical applications to complex systemic infections. This trend is expected to significantly influence market growth, as customized and effective delivery systems make bacteriophage therapy a viable option across a wider range of medical conditions.
Bacteriophage Therapy Market Segment Analysis:
Bacteriophage Therapy Market is Segmented on the basis of Target, Type, Base, Application, Route of Administration, Distribution Channel, and Region
By Target, Escherichia Coli segment is expected to dominate the market during the forecast period
- In the Bacteriophage Therapy Market, targeting specific bacterial pathogens has become a focal point, with therapies being developed for high-priority bacteria such as Escherichia coli, Staphylococcus, Streptococcus, Pseudomonas, and Salmonella. Each of these bacteria is associated with various infections, often resistant to traditional antibiotics, thus driving demand for bacteriophage-based solutions that offer precision in targeting specific pathogens. For instance, Escherichia coli and Pseudomonas bacteriophages are actively researched for urinary tract and respiratory infections, respectively, while Staphylococcus and Streptococcus phages hold potential for skin infections and conditions like strep throat. This segmentation of the market by target pathogen allows for specialized development of phages that are optimized for specific bacterial types, increasing efficacy and reducing off-target effects, which is critical as antibiotic resistance continues to challenge healthcare providers worldwide. The targeted approach also accelerates regulatory approval and enhances therapeutic success, positioning bacteriophage therapy as a valuable asset in precision medicine.
By Distribution Channel, Hospital Pharmacy segment expected to held the largest share
- In the Bacteriophage Therapy Market, distribution channels are pivotal in ensuring that these specialized treatments reach patients effectively and efficiently. Hospital pharmacies dominate as the primary channel, given the current clinical and specialized nature of bacteriophage treatments, which are often administered under medical supervision to treat severe or multidrug-resistant infections. Retail pharmacies are beginning to gain traction in markets where bacteriophage-based products are approved for outpatient use, especially for conditions like wound care and gastrointestinal disorders. Online pharmacies are also emerging as an accessible option, particularly for countries that permit direct-to-consumer sales of bacteriophage treatments, increasing patient access and convenience. Other channels, such as specialty clinics, further diversify access, particularly for patients seeking advanced and personalized bacteriophage treatments in regions where regulatory frameworks permit their use outside hospitals.
Bacteriophage Therapy Market Regional Insights:
North America is Expected to Dominate the Market Over the Forecast period
- North America is expected to dominate the Bacteriophage Therapy Market over the forecast period, driven by strong research funding, a supportive regulatory environment, and the presence of key biotechnology firms advancing bacteriophage research and development. The region’s high prevalence of antibiotic-resistant infections and the demand for innovative treatment options have spurred both private and public investments into bacteriophage therapy as a promising alternative to traditional antibiotics. Additionally, North America benefits from a well-established healthcare infrastructure that facilitates the adoption of new therapies, with increasing numbers of clinical trials validating bacteriophage effectiveness for conditions such as respiratory infections, gastrointestinal disorders, and chronic wound care. This leadership in R&D and clinical applications is expected to sustain North America’s dominant position in the market as more bacteriophage therapies move towards commercialization and clinical integration.
Active Key Players in the Bacteriophage Therapy Market:
- Microgen (U.S.),
- Micreos (Netherlands),
- ATCC (U.S.),
- Intralytix, Inc. (U.S.),
- Adaptive Phage Therapeutics (U.S.),
- Armata pharmaceuticals Inc. (U.S.),
- LOCUS BIOSCIENCES, INC. (U.S.),
- Delmont Laboratories, Inc. (U.S.),
- Nextbiotics (U.S.),
- Pherecydes Pharma (France),
- iNtODEWORLD. Inc. (U.S.),
- Enbiotix (U.S.),
- Fixed-Phage Limited (U.K.),
- Cytophage Technologies Inc. (Canada),
- Eliava Bio Preparations LTD (Georgia),
- Phagelux, Inc. (China),
- InnoPhage, Ltd (Hong Kong),
- TechnoPhage (Portugal),
- Eligo Bioscience SA (France),
- BiomX Ltd. (Israel)
- Other Active Players
|
Global Bacteriophage Therapy Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 1.32 Billion |
|
Forecast Period 2024-32 CAGR: |
3.89% |
Market Size in 2032: |
USD 1.87 Billion |
|
Segments Covered: |
By Target |
|
|
|
By Base |
|
||
|
By Type |
|
||
|
By Application |
|
||
|
By Route Of Administration |
|
||
|
By End-Users |
|
||
|
By Distribution Channel |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Bacteriophage Therapy Market by By Target (2018-2032)
4.1 Bacteriophage Therapy Market Snapshot and Growth Engine
4.2 Market Overview
4.3 Escherichia Coli
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
4.3.3 Key Market Trends, Growth Factors, and Opportunities
4.3.4 Geographic Segmentation Analysis
4.4 Staphylococcus
4.5 Streptococcus
4.6 Pseudomonas
4.7 Salmonella
4.8 Others
Chapter 5: Bacteriophage Therapy Market by By Base (2018-2032)
5.1 Bacteriophage Therapy Market Snapshot and Growth Engine
5.2 Market Overview
5.3 Sterile Broth Culture
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
5.3.3 Key Market Trends, Growth Factors, and Opportunities
5.3.4 Geographic Segmentation Analysis
5.4 Water-Soluble Jelly Base
Chapter 6: Bacteriophage Therapy Market by By Type (2018-2032)
6.1 Bacteriophage Therapy Market Snapshot and Growth Engine
6.2 Market Overview
6.3 Lytic
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
6.3.3 Key Market Trends, Growth Factors, and Opportunities
6.3.4 Geographic Segmentation Analysis
6.4 Lysogenic
Chapter 7: Bacteriophage Therapy Market by By Application (2018-2032)
7.1 Bacteriophage Therapy Market Snapshot and Growth Engine
7.2 Market Overview
7.3 Bacterial Dysentery
7.3.1 Introduction and Market Overview
7.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
7.3.3 Key Market Trends, Growth Factors, and Opportunities
7.3.4 Geographic Segmentation Analysis
7.4 Infections of Skin and Nasal Mucosa
7.5 Suppurative Skin Infection
7.6 Lung And Pleural Infections
7.7 Postoperative Wound Infections
7.8 Others
Chapter 8: Bacteriophage Therapy Market by By Route Of Administration (2018-2032)
8.1 Bacteriophage Therapy Market Snapshot and Growth Engine
8.2 Market Overview
8.3 Oral
8.3.1 Introduction and Market Overview
8.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
8.3.3 Key Market Trends, Growth Factors, and Opportunities
8.3.4 Geographic Segmentation Analysis
8.4 Parenteral
8.5 Rectal
8.6 Dermal
8.7 Others
Chapter 9: Bacteriophage Therapy Market by By End-Users (2018-2032)
9.1 Bacteriophage Therapy Market Snapshot and Growth Engine
9.2 Market Overview
9.3 Hospitals
9.3.1 Introduction and Market Overview
9.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
9.3.3 Key Market Trends, Growth Factors, and Opportunities
9.3.4 Geographic Segmentation Analysis
9.4 Specialty Clinics
9.5 Homecare
9.6 Others
Chapter 10: Company Profiles and Competitive Analysis
10.1 Competitive Landscape
10.1.1 Competitive Benchmarking
10.1.2 Bacteriophage Therapy Market Share by Manufacturer (2024)
10.1.3 Industry BCG Matrix
10.1.4 Heat Map Analysis
10.1.5 Mergers and Acquisitions
10.2 MICROGEN (U.S.)
10.2.1 Company Overview
10.2.2 Key Executives
10.2.3 Company Snapshot
10.2.4 Role of the Company in the Market
10.2.5 Sustainability and Social Responsibility
10.2.6 Operating Business Segments
10.2.7 Product Portfolio
10.2.8 Business Performance
10.2.9 Key Strategic Moves and Recent Developments
10.2.10 SWOT Analysis
10.3 MICREOS (NETHERLANDS)
10.4 ATCC (U.S.)
10.5 INTRALYTIX INC. (U.S.)
10.6 ADAPTIVE PHAGE THERAPEUTICS (U.S.)
10.7 ARMATA PHARMACEUTICALS INC. (U.S.)
10.8 LOCUS BIOSCIENCES INC. (U.S.)
10.9 DELMONT LABORATORIES INC. (U.S.)
10.10 NEXTBIOTICS (U.S.)
10.11 PHERECYDES PHARMA (FRANCE)
10.12 INTODEWORLD. INC. (U.S.)
10.13 ENBIOTIX (U.S.)
10.14 FIXED-PHAGE LIMITED (U.K.)
10.15 CYTOPHAGE TECHNOLOGIES INC. (CANADA)
10.16 ELIAVA BIO PREPARATIONS LTD (GEORGIA)
10.17 PHAGELUX INC. (CHINA)
10.18 INNOPHAGE LTD (HONG KONG)
10.19 TECHNOPHAGE (PORTUGAL)
10.20 ELIGO BIOSCIENCE SA (FRANCE)
10.21 BIOMX LTD. (ISRAEL)
10.22 OTHER ACTIVE PLAYERS
Chapter 11: Global Bacteriophage Therapy Market By Region
11.1 Overview
11.2. North America Bacteriophage Therapy Market
11.2.1 Key Market Trends, Growth Factors and Opportunities
11.2.2 Top Key Companies
11.2.3 Historic and Forecasted Market Size by Segments
11.2.4 Historic and Forecasted Market Size By By Target
11.2.4.1 Escherichia Coli
11.2.4.2 Staphylococcus
11.2.4.3 Streptococcus
11.2.4.4 Pseudomonas
11.2.4.5 Salmonella
11.2.4.6 Others
11.2.5 Historic and Forecasted Market Size By By Base
11.2.5.1 Sterile Broth Culture
11.2.5.2 Water-Soluble Jelly Base
11.2.6 Historic and Forecasted Market Size By By Type
11.2.6.1 Lytic
11.2.6.2 Lysogenic
11.2.7 Historic and Forecasted Market Size By By Application
11.2.7.1 Bacterial Dysentery
11.2.7.2 Infections of Skin and Nasal Mucosa
11.2.7.3 Suppurative Skin Infection
11.2.7.4 Lung And Pleural Infections
11.2.7.5 Postoperative Wound Infections
11.2.7.6 Others
11.2.8 Historic and Forecasted Market Size By By Route Of Administration
11.2.8.1 Oral
11.2.8.2 Parenteral
11.2.8.3 Rectal
11.2.8.4 Dermal
11.2.8.5 Others
11.2.9 Historic and Forecasted Market Size By By End-Users
11.2.9.1 Hospitals
11.2.9.2 Specialty Clinics
11.2.9.3 Homecare
11.2.9.4 Others
11.2.10 Historic and Forecast Market Size by Country
11.2.10.1 US
11.2.10.2 Canada
11.2.10.3 Mexico
11.3. Eastern Europe Bacteriophage Therapy Market
11.3.1 Key Market Trends, Growth Factors and Opportunities
11.3.2 Top Key Companies
11.3.3 Historic and Forecasted Market Size by Segments
11.3.4 Historic and Forecasted Market Size By By Target
11.3.4.1 Escherichia Coli
11.3.4.2 Staphylococcus
11.3.4.3 Streptococcus
11.3.4.4 Pseudomonas
11.3.4.5 Salmonella
11.3.4.6 Others
11.3.5 Historic and Forecasted Market Size By By Base
11.3.5.1 Sterile Broth Culture
11.3.5.2 Water-Soluble Jelly Base
11.3.6 Historic and Forecasted Market Size By By Type
11.3.6.1 Lytic
11.3.6.2 Lysogenic
11.3.7 Historic and Forecasted Market Size By By Application
11.3.7.1 Bacterial Dysentery
11.3.7.2 Infections of Skin and Nasal Mucosa
11.3.7.3 Suppurative Skin Infection
11.3.7.4 Lung And Pleural Infections
11.3.7.5 Postoperative Wound Infections
11.3.7.6 Others
11.3.8 Historic and Forecasted Market Size By By Route Of Administration
11.3.8.1 Oral
11.3.8.2 Parenteral
11.3.8.3 Rectal
11.3.8.4 Dermal
11.3.8.5 Others
11.3.9 Historic and Forecasted Market Size By By End-Users
11.3.9.1 Hospitals
11.3.9.2 Specialty Clinics
11.3.9.3 Homecare
11.3.9.4 Others
11.3.10 Historic and Forecast Market Size by Country
11.3.10.1 Russia
11.3.10.2 Bulgaria
11.3.10.3 The Czech Republic
11.3.10.4 Hungary
11.3.10.5 Poland
11.3.10.6 Romania
11.3.10.7 Rest of Eastern Europe
11.4. Western Europe Bacteriophage Therapy Market
11.4.1 Key Market Trends, Growth Factors and Opportunities
11.4.2 Top Key Companies
11.4.3 Historic and Forecasted Market Size by Segments
11.4.4 Historic and Forecasted Market Size By By Target
11.4.4.1 Escherichia Coli
11.4.4.2 Staphylococcus
11.4.4.3 Streptococcus
11.4.4.4 Pseudomonas
11.4.4.5 Salmonella
11.4.4.6 Others
11.4.5 Historic and Forecasted Market Size By By Base
11.4.5.1 Sterile Broth Culture
11.4.5.2 Water-Soluble Jelly Base
11.4.6 Historic and Forecasted Market Size By By Type
11.4.6.1 Lytic
11.4.6.2 Lysogenic
11.4.7 Historic and Forecasted Market Size By By Application
11.4.7.1 Bacterial Dysentery
11.4.7.2 Infections of Skin and Nasal Mucosa
11.4.7.3 Suppurative Skin Infection
11.4.7.4 Lung And Pleural Infections
11.4.7.5 Postoperative Wound Infections
11.4.7.6 Others
11.4.8 Historic and Forecasted Market Size By By Route Of Administration
11.4.8.1 Oral
11.4.8.2 Parenteral
11.4.8.3 Rectal
11.4.8.4 Dermal
11.4.8.5 Others
11.4.9 Historic and Forecasted Market Size By By End-Users
11.4.9.1 Hospitals
11.4.9.2 Specialty Clinics
11.4.9.3 Homecare
11.4.9.4 Others
11.4.10 Historic and Forecast Market Size by Country
11.4.10.1 Germany
11.4.10.2 UK
11.4.10.3 France
11.4.10.4 The Netherlands
11.4.10.5 Italy
11.4.10.6 Spain
11.4.10.7 Rest of Western Europe
11.5. Asia Pacific Bacteriophage Therapy Market
11.5.1 Key Market Trends, Growth Factors and Opportunities
11.5.2 Top Key Companies
11.5.3 Historic and Forecasted Market Size by Segments
11.5.4 Historic and Forecasted Market Size By By Target
11.5.4.1 Escherichia Coli
11.5.4.2 Staphylococcus
11.5.4.3 Streptococcus
11.5.4.4 Pseudomonas
11.5.4.5 Salmonella
11.5.4.6 Others
11.5.5 Historic and Forecasted Market Size By By Base
11.5.5.1 Sterile Broth Culture
11.5.5.2 Water-Soluble Jelly Base
11.5.6 Historic and Forecasted Market Size By By Type
11.5.6.1 Lytic
11.5.6.2 Lysogenic
11.5.7 Historic and Forecasted Market Size By By Application
11.5.7.1 Bacterial Dysentery
11.5.7.2 Infections of Skin and Nasal Mucosa
11.5.7.3 Suppurative Skin Infection
11.5.7.4 Lung And Pleural Infections
11.5.7.5 Postoperative Wound Infections
11.5.7.6 Others
11.5.8 Historic and Forecasted Market Size By By Route Of Administration
11.5.8.1 Oral
11.5.8.2 Parenteral
11.5.8.3 Rectal
11.5.8.4 Dermal
11.5.8.5 Others
11.5.9 Historic and Forecasted Market Size By By End-Users
11.5.9.1 Hospitals
11.5.9.2 Specialty Clinics
11.5.9.3 Homecare
11.5.9.4 Others
11.5.10 Historic and Forecast Market Size by Country
11.5.10.1 China
11.5.10.2 India
11.5.10.3 Japan
11.5.10.4 South Korea
11.5.10.5 Malaysia
11.5.10.6 Thailand
11.5.10.7 Vietnam
11.5.10.8 The Philippines
11.5.10.9 Australia
11.5.10.10 New Zealand
11.5.10.11 Rest of APAC
11.6. Middle East & Africa Bacteriophage Therapy Market
11.6.1 Key Market Trends, Growth Factors and Opportunities
11.6.2 Top Key Companies
11.6.3 Historic and Forecasted Market Size by Segments
11.6.4 Historic and Forecasted Market Size By By Target
11.6.4.1 Escherichia Coli
11.6.4.2 Staphylococcus
11.6.4.3 Streptococcus
11.6.4.4 Pseudomonas
11.6.4.5 Salmonella
11.6.4.6 Others
11.6.5 Historic and Forecasted Market Size By By Base
11.6.5.1 Sterile Broth Culture
11.6.5.2 Water-Soluble Jelly Base
11.6.6 Historic and Forecasted Market Size By By Type
11.6.6.1 Lytic
11.6.6.2 Lysogenic
11.6.7 Historic and Forecasted Market Size By By Application
11.6.7.1 Bacterial Dysentery
11.6.7.2 Infections of Skin and Nasal Mucosa
11.6.7.3 Suppurative Skin Infection
11.6.7.4 Lung And Pleural Infections
11.6.7.5 Postoperative Wound Infections
11.6.7.6 Others
11.6.8 Historic and Forecasted Market Size By By Route Of Administration
11.6.8.1 Oral
11.6.8.2 Parenteral
11.6.8.3 Rectal
11.6.8.4 Dermal
11.6.8.5 Others
11.6.9 Historic and Forecasted Market Size By By End-Users
11.6.9.1 Hospitals
11.6.9.2 Specialty Clinics
11.6.9.3 Homecare
11.6.9.4 Others
11.6.10 Historic and Forecast Market Size by Country
11.6.10.1 Turkiye
11.6.10.2 Bahrain
11.6.10.3 Kuwait
11.6.10.4 Saudi Arabia
11.6.10.5 Qatar
11.6.10.6 UAE
11.6.10.7 Israel
11.6.10.8 South Africa
11.7. South America Bacteriophage Therapy Market
11.7.1 Key Market Trends, Growth Factors and Opportunities
11.7.2 Top Key Companies
11.7.3 Historic and Forecasted Market Size by Segments
11.7.4 Historic and Forecasted Market Size By By Target
11.7.4.1 Escherichia Coli
11.7.4.2 Staphylococcus
11.7.4.3 Streptococcus
11.7.4.4 Pseudomonas
11.7.4.5 Salmonella
11.7.4.6 Others
11.7.5 Historic and Forecasted Market Size By By Base
11.7.5.1 Sterile Broth Culture
11.7.5.2 Water-Soluble Jelly Base
11.7.6 Historic and Forecasted Market Size By By Type
11.7.6.1 Lytic
11.7.6.2 Lysogenic
11.7.7 Historic and Forecasted Market Size By By Application
11.7.7.1 Bacterial Dysentery
11.7.7.2 Infections of Skin and Nasal Mucosa
11.7.7.3 Suppurative Skin Infection
11.7.7.4 Lung And Pleural Infections
11.7.7.5 Postoperative Wound Infections
11.7.7.6 Others
11.7.8 Historic and Forecasted Market Size By By Route Of Administration
11.7.8.1 Oral
11.7.8.2 Parenteral
11.7.8.3 Rectal
11.7.8.4 Dermal
11.7.8.5 Others
11.7.9 Historic and Forecasted Market Size By By End-Users
11.7.9.1 Hospitals
11.7.9.2 Specialty Clinics
11.7.9.3 Homecare
11.7.9.4 Others
11.7.10 Historic and Forecast Market Size by Country
11.7.10.1 Brazil
11.7.10.2 Argentina
11.7.10.3 Rest of SA
Chapter 12 Analyst Viewpoint and Conclusion
12.1 Recommendations and Concluding Analysis
12.2 Potential Market Strategies
Chapter 13 Research Methodology
13.1 Research Process
13.2 Primary Research
13.3 Secondary Research
|
Global Bacteriophage Therapy Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 1.32 Billion |
|
Forecast Period 2024-32 CAGR: |
3.89% |
Market Size in 2032: |
USD 1.87 Billion |
|
Segments Covered: |
By Target |
|
|
|
By Base |
|
||
|
By Type |
|
||
|
By Application |
|
||
|
By Route Of Administration |
|
||
|
By End-Users |
|
||
|
By Distribution Channel |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
Frequently Asked Questions :
The forecast period in the Bacteriophage Therapy Market research report is 2024-2032.
Microgen (U.S.), Micreos (Netherlands), ATCC (U.S.), Intralytix, Inc. (U.S.), Adaptive Phage Therapeutics (U.S.), Armata Pharmaceuticals Inc. (U.S.), LOCUS BIOSCIENCES, INC. (U.S.), Delmont Laboratories, Inc. (U.S.), Nextbiotics (U.S.), Pherecydes Pharma (France), iNtODEWORLD. Inc. (U.S.), Enbiotix (U.S.), Fixed-Phage Limited (U.K.), Cytophage Technologies Inc. (Canada), Eliava Bio Preparations LTD (Georgia), Phagelux, Inc. (China), InnoPhage, Ltd (Hong Kong), TechnoPhage (Portugal), Eligo Bioscience SA (France), BiomX Ltd. (Israel), and Other Active Players.
The Bacteriophage Therapy Market is segmented into By Target, Type, Base, Application, Route of Administration, End User, Distribution Channel and region. By Target (Escherichia Coli, Staphylococcus, Streptococcus, Pseudomonas, Salmonella, Others), Type (Lytic, Lysogenic), Base (Sterile Broth Culture, Water-Soluble Jelly Base), Application (Bacterial Dysentery, Infections Of Skin And Nasal Mucosa, Suppurative Skin Infection, Lung And Pleural Infections, Postoperative Wound Infections, Others), Route Of Administration (Oral, Parenteral, Rectal, Dermal, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others). By region, it is analyzed across North America (U.S., Canada, Mexico), Eastern Europe (Russia, Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe), Western Europe (Germany, UK, France, The Netherlands, Italy, Spain, Rest of Western Europe), Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New-Zealand, Rest of APAC), Middle East & Africa (Turkiye, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa), South America (Brazil, Argentina, Rest of SA).
Bacteriophage therapy is a medical treatment that uses bacteriophages—viruses that specifically infect and destroy bacteria—to combat bacterial infections. Unlike antibiotics, which can broadly target both harmful and beneficial bacteria, bacteriophages are highly specific, attacking only particular strains of bacteria while leaving the surrounding microbiota unaffected. This precision makes bacteriophage therapy a promising alternative, especially for infections that are resistant to antibiotics. Leveraging naturally occurring or genetically engineered phages, this approach is being explored in various applications, from wound healing to gastrointestinal and respiratory infections, presenting a novel and targeted way to manage bacterial diseases.
The Bacteriophage Therapy Market Was Valued at USD 1.32 Billion in 2023 and is Projected to Reach USD 1.87 Billion by 2032, Growing at a CAGR of 3.89 % from 2024 to 2032.
